All In Biotech

NDA 019931 · Bausch

Klaron

Sulfacetamide Sodium · Topical

Last checked: Nov 20, 2026Latest source record: Feb 16, 2016 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1996

Dec 23, 1996

Approved uses

1

Original approval plus efficacy supplements

Registered trials

2

0 Phase 3, 0 recruiting

FAERS reports

580

250 serious, 15 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 31, 2020.

INDICATIONS Klaron Lotion is indicated in the topical treatment of acne vulgaris .

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 23, 1996 Original approval · Type 3 - New Dosage Form Review
1 products under this application
  • KLARON · SULFACETAMIDE SODIUM 10% · LOTION, TOPICAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Sulfacetamide" as an intervention, any sponsor and status, largest first.

All 2 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug hypersensitivity66
  • drug ineffective55
  • nausea36
  • off label use35
  • headache31
  • pain30
  • dyspnoea29
  • rash28
  • fatigue25
  • weight decreased24
  • vomiting20
  • diarrhoea19

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20042
200510
20063
20078
20085
200912
201020
201114
201218
201325
201413
201525
201649
201738
201842
201954
202031
202125
202249
202335
202432
202535
202635

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 20 on PubMed

Sponsor: Bausch

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.